NovoCure (NVCR) Cash & Equivalents (2014 - 2026)

NovoCure has disclosed Cash & Equivalents across 13 years of filings, most recently posting $87.5 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $87.5 million, down 31.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $87.5 million (down 31.23% YoY), and the FY2025 annual result was $93.5 million, down 42.88% from the prior year.
• Cash & Equivalents came in at $87.5 million for Q1 2026 at NovoCure, down from $93.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $453.8 million in Q1 2024 to a low of $87.5 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $164.8 million (2024), against an average of $201.4 million.
• Across the five-year window, Cash & Equivalents surged 144.01% in 2024 and sank 71.95% in 2025, its largest moves.
• NovoCure's Cash & Equivalents stood at $115.3 million in 2022, then soared by 108.82% to $240.8 million in 2023, then plunged by 32.0% to $163.8 million in 2024, then sank by 42.88% to $93.5 million in 2025, then declined by 6.44% to $87.5 million in 2026.
• The last three Cash & Equivalents figures came in at $87.5 million (Q1 2026), $93.5 million (Q4 2025), and $342.1 million (Q3 2025), per Business Quant data.